Edition:
India

Silence Therapeutics PLC (SLN.L)

SLN.L on London Stock Exchange

82.50GBp
15 Jul 2019
Change (% chg)

-1.25 (-1.49%)
Prev Close
83.75
Open
85.00
Day's High
85.00
Day's Low
82.50
Volume
150,282
Avg. Vol
215,983
52-wk High
175.00
52-wk Low
40.00

Latest Key Developments (Source: Significant Developments)

Silence Therapeutics Appoints Rob Quinn As Full Time CFO
Thursday, 18 Apr 2019 

April 18 (Reuters) - Silence Therapeutics PLC ::APPOINTMENT OF CHIEF FINANCIAL OFFICER.APPOINTMENT OF ROB QUINN AS FULL TIME CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

Silence Therapeutics Says Andy Richards To Leave Role As Interim Non-Executive Chair
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Silence Therapeutics PLC ::ANDY RICHARDS IS LEAVING HIS ROLE AS INTERIM NON-EXECUTIVE CHAIR AND A DIRECTOR OF COMPANY.COMPANY'S PREVIOUSLY ANNOUNCED PROCESS TO APPOINT A NEW CHAIR IS ONGOING.  Full Article

Silence Therapeutics Says SLN124 Granted Orphan Drug Designation By EMA
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Silence Therapeutics PLC ::SILENCE THERAPEUTICS - SLN124 GRANTED ORPHAN DRUG DESIGNATION BY EMA.SILENCE THERAPEUTICS PLC - LEAD MEDICINE CANDIDATE SLN124 HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS.  Full Article

Silence Therapeutics Says David Ellam Steps Down As CFO
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Silence Therapeutics PLC ::DEPARTURE OF CHIEF FINANCIAL OFFICER.DEPARTURE OF DAVID ELLAM, ITS CHIEF FINANCIAL OFFICER, WITH IMMEDIATE EFFECT.DR ROB QUINN WILL SERVE AS INTERIM CFO UNTIL A NEW CFO IS APPOINTED.  Full Article

Silence Therapeutics Says Appoints David Horn Solomon As CEO
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Silence Therapeutics PLC ::APPOINTS DAVID HORN SOLOMON AS CEO.DAVID WILL HEAD LEADERSHIP TEAM AND JOINS BOARD OF DIRECTORS.SAYS APPOINTMENT OF SOLOMON EFFECTIVE IMMEDIATELY.APPOINTMENT OF DAVID HORN SOLOMON AS ITS NEW CHIEF EXECUTIVE OFFICER (CEO) EFFECTIVE IMMEDIATELY.  Full Article

Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Silence Therapeutics Plc ::‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​.DEAL ‍FOR A TOTAL CONSIDERATION OF $11.3 MILLION​.  Full Article

Silence Therapeutics Says Sold Part Of Holding Of Common Shares In Arrowhead Pharmaceuticals
Monday, 4 Dec 2017 

Dec 4 (Reuters) - SILENCE THERAPEUTICS PLC ::THAT IT HAS SOLD PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC​.‍COMPANY HAS SOLD 2,036,046 SHARES ON OPEN MARKET FOR $7.5 MILLION​.  Full Article